The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan.
One hundred seventy-one patients with chronic hepatitis C were included in this study (genotype1 and high viral loads (1H), [Formula: see text]; non-1H, [Formula: see text]; N.D., [Formula: see text] ). The combination therapy of interferon and ribavirin for 24 weeks with an additional 24 weeks of interferon monotherapy (48-week treatment) was undergone by 42 1H patients and 5 non-1H patients. The combination therapy of interferon and ribavirin was administered for 24 weeks in 67 1H patients and 22 non-1H patients. Among the 1H patients, the HCV relapse rate was significantly higher in those receiving 24-week combination treatment than in those receiving 48-week treatment (78% versus 42%, [Formula: see text] ). Among the non-1H patients, no significant difference was found between them. Sustained virological response (SVR) rates were observed to decrease as the timing of HCV RNA disappearance was delayed. In spite of the small rate (16%), SVR was obtained from the patients who became negative for HCV RNA by week 24 (beyond week 12) only in those receiving 48-week treatment. In 1H patients, 24-week combination treatment followed by interferon monotherapy for 24 weeks was concluded to be the treatment offering the most hope among those that the medical insurance can be applied in Japan.
Hiramatsu
Naoki
N
Department of Molecular Therapeutics, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita City, Osaka 565-0871, Japan.
Kasahara
Akinori
A
Nakanishi
Fumihiko
F
Toyama
Takashi
T
Tsujii
Masahiko
M
Tsuji
Shingo
S
Kanto
Tatsuya
T
Takehara
Tetsuo
T
Kato
Michio
M
Yoshihara
Harumasa
H
Naito
Masafumi
M
Katayama
Kazuhiro
K
Hijioka
Taizo
T
Hagiwara
Hideki
H
Kubota
Shinji
S
Oshita
Masahide
M
Meren
Haruya
H
Masuzawa
Manabu
M
Haruna
Yoshimichi
Y
Mita
Eiji
E
Suzuki
Kunio
K
Hayashi
Norio
N